Published in Eur Heart J on February 01, 1997
Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. Circ Heart Fail (2011) 2.28
Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax (2005) 1.71
Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart (2000) 1.58
Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle (2012) 1.21
Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones. J Cachexia Sarcopenia Muscle (2014) 0.92
Comparison of skeletal muscle strength between cardiac patients and age-matched healthy controls. Int J Med Sci (2009) 0.89
Update on melanocortin interventions for cachexia: progress toward clinical application. Nutrition (2009) 0.89
Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes? Mol Cell Endocrinol (2011) 0.84
Plasma amino acid profiling identifies specific amino acid associations with cardiovascular function in patients with systolic heart failure. PLoS One (2015) 0.82
The role of exercise training in chronic heart failure. Heart (1997) 0.82
Effects of exercise training on neurovascular control and skeletal myopathy in systolic heart failure. Am J Physiol Heart Circ Physiol (2015) 0.81
Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle. J Cachexia Sarcopenia Muscle (2011) 0.80
Chronic heart failure and exercise intolerance: the hemodynamic paradox. Curr Cardiol Rev (2008) 0.78
Lower body mass index and atrial fibrillation as independent predictors for mortality in patients with implantable cardioverter defibrillator. Croat Med J (2007) 0.78
Improved Ventilatory Efficiency with Locomotor Muscle Afferent Inhibition is Strongly Associated with Leg Composition in Heart Failure. Int J Cardiol (2015) 0.76
Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions. BMC Musculoskelet Disord (2011) 0.76
Report of a Joint Cancer Research UK/Medical Research Council workshop on cancer cachexia research at the Royal College of Physicians, Tuesday, 2 December 2003. Br J Cancer (2005) 0.75
Malnutrition and Gut Flora Dysbiosis: Specific Therapies for Emerging Comorbidities in Heart Failure. Biomed Res Int (2015) 0.75
The importance of cachexia in the syndrome of heart failure. Eur Heart J (1997) 0.75
Metabolic profiles in heart failure due to non-ischemic cardiomyopathy at rest and under exercise. ESC Heart Fail (2017) 0.75
Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia. Sci Rep (2017) 0.75
Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol (1997) 16.86
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (1997) 6.48
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J (2000) 4.99
Incidence and aetiology of heart failure; a population-based study. Eur Heart J (1999) 4.56
The epidemiology of heart failure. Eur Heart J (1997) 4.31
Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet (1993) 3.56
Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J (2001) 3.49
Wasting as independent risk factor for mortality in chronic heart failure. Lancet (1997) 3.37
Thiamine in our bread and wine? Med J Aust (1990) 3.09
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
The endotoxin-lipoprotein hypothesis. Lancet (2000) 3.03
Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 3.01
Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol (1995) 2.89
Prevalence of heart failure in three general practices in north west London. Br J Gen Pract (1992) 2.88
Survival of patients with a new diagnosis of heart failure: a population based study. Heart (2000) 2.86
Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2000) 2.85
Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J (1998) 2.73
Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation (1997) 2.69
Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet (2003) 2.64
Heart failure in a district general hospital. J R Coll Physicians Lond (1992) 2.61
Hospitalization of patients with heart failure: a population-based study. Eur Heart J (2002) 2.54
Practice nurses' workload and consultation patterns. Br J Gen Pract (1995) 2.50
Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax (2001) 2.50
17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation (1995) 2.49
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49
Knowledge and communication difficulties for patients with chronic heart failure: qualitative study. BMJ (2000) 2.47
Screening for hypertrophic cardiomyopathy. BMJ (1993) 2.31
Pathogenesis of edema in constrictive pericarditis. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones before and after pericardiectomy. Circulation (1991) 2.28
Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1997) 2.27
Downregulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation (1998) 2.26
Hypothesis: inhibition of endothelium-derived relaxing factor by haemoglobin in the pathogenesis of pre-eclampsia. Lancet (1990) 2.24
Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol (1997) 2.19
Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation (2000) 2.18
Respiratory gas exchange in the assessment of patients with impaired ventricular function. Br Heart J (1985) 2.17
Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha. Eur Heart J (1999) 2.12
Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet (1997) 2.09
Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J (Clin Res Ed) (1986) 2.09
Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol (1997) 2.08
Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Clin Pharmacol Ther (1999) 2.06
Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). Eur Heart J (2000) 2.06
Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol (1997) 2.05
Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation (1993) 2.05
Second trimester ambulatory blood pressure in nulliparous pregnancy: a useful screening test for pre-eclampsia? Br J Obstet Gynaecol (1993) 2.04
Mechanism of the increased ventilatory response to exercise in patients with chronic heart failure. Br Heart J (1990) 2.00
Severity of heart failure and dosage of angiotensin converting enzyme inhibitors. BMJ (1995) 1.99
Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J (2002) 1.98
Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J (1998) 1.97
Hypoxia and calcium. J Mol Cell Cardiol (1979) 1.94
Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation (1996) 1.88
The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J (2004) 1.84
Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. Am J Cardiol (2001) 1.79
Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol (1996) 1.76
Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation (2001) 1.75
Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. Eur Heart J (2004) 1.74
Quantitative general theory for periodic breathing in chronic heart failure and its clinical implications. Circulation (2000) 1.72
Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol (2001) 1.71
Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol (1999) 1.71
Right ventricular diastolic function 15 to 35 years after repair of tetralogy of Fallot. Restrictive physiology predicts superior exercise performance. Circulation (1995) 1.70
First permanent implant of the Jarvik 2000 Heart. Lancet (2000) 1.68
Abnormalities of skeletal muscle in patients with chronic heart failure. Int J Cardiol (1988) 1.66
Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure. Eur Heart J (2000) 1.66
Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol (1997) 1.63
Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol (1993) 1.62
Heart failure: why and how to define it? Eur J Heart Fail (1999) 1.61
Menopause and cardiovascular disease: the evidence. Climacteric (2007) 1.60
Maintenance oral nifedipine for preterm labor: a randomized clinical trial. Am J Obstet Gynecol (1999) 1.60
Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart (2000) 1.58
Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J (1993) 1.58
Characteristics of phasic and tonic sympathetic ganglion cells of the guinea-pig. J Physiol (1986) 1.57
Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J (1997) 1.55